Endeavor's Hedgehog inhibitor posts phase 2 win, threatening IPF incumbents
Start here
Endeavor has reported positive phase 2 results for its Hedgehog pathway inhibitor in idiopathic pulmonary fibrosis (IPF), a result that community discussion suggests could threaten the market position of current IPF therapies. The outcome marks the company's first major clinical readout in the indication and positions it as a potential challenger to established treatments. Details of the trial design, efficacy endpoints and safety profile beyond the reported win have not been disclosed in the coverage so far. Key open questions include whether the findings will support advancement into later-stage testing, how regulators respond, and how incumbent IPF drugmakers react to the new competitive threat.
Written by a model from the reports · updated 3 hours ago
Coverage timeline
Follow the coverage to see the different angles.
- RedditPickEndeavor’s threat to IPF incumbents increases after phase 2 win for Hedgehog inhibitor
Endeavor's Hedgehog pathway inhibitor taladegib (ENV-101) met the ppFVC primary endpoint in the phase 2b WHISTLE-PF trial in IPF, and the company plans to advance to phase 3. The trial enrolled 213 patients across 74 centers in 14 countries, with results announced on 2026-10-08. The mechanism differs from existing pirfenidone and nintedanib; the poster sees it as a potential threat to current IPF therapies, but phase 2b success does not guarantee phase 3 or approval.
Coverage and heat for this story
Reports so far 1·Heat now 8·Peak heat 10 (Oct 19 14:00)·Reports, 24h +1
Two panels, same clock (pointer stays in sync): top is cumulative editorial reports — only rises; last point = All reports; slope = new reports that hour. Bottom is Live-board heatIndex — 7-day participants with a 24-hour half-life, so it can fall when talk cools.